The history of the antithrombotic agents-aspirin, heparin, warfarin, and the thrombolytics -is a rich and lively odyssey of serendipity, perseverance, vision, and conflict involving a number of striking personalities. The history of aspirin spans ages and continents from Hippocrates' analgesic for women in labor to the rediscovery of the white willow bark by English country scholar Reverend Edward Stone. Bayer chemist Felix Hoffmann reinvented aspirin for his ailing father; suburban physician L.L. Craven pioneered the prophylactic antithrombotic uses of aspirin; and Sir John Vane elucidated aspirin's mechanism of action as the inhibition of prostaglandin synthetase. Heparin was discovered by McLean, working as a medical student in 1915 in search of a pure procoagulant in dog liver. His original impure material differed somewhat from today's heparin, but purified heparin was rapidly accepted for a myriad of clinical uses; to this day, diverse new properties of this complex glycosaminoglycan continue to be elucidated. The oral anticoagulants emerged from veterinary research in the 1920s on a hemorrhagic disorder afflicting cattle that consumed spoiled sweet clover hay. Several chance encounters led Karl Link and his University of Wisconsin team to the identification of dicumarol as the offending agent in 1939 and nhe history of the discovery and development of agents for the treatment of thrombotic disorders (antiplatelet agents, anticoagulants, and thrombolytics) is rich in historical lessons; replete with fascinating, charismatic, and often eccentric personalities; and above all is a long odyssey of stunning medical advances. The stories begin with diverse settings, problems, and personalities, but all culminate in seminal advances in the understanding of vascular biology and hemostasis and in stunning therapeutic innovations.
Most of the sagas involve serendipitous findings, encounters, or twists of fate, which so often surround scientific advances. Many of the discoveries were made by individuals with little direct experience in the new fields where their research had led them. Rather than abandoning their work when faced with frustrating and inexplicable findings, they pursued interesting leads that often led them in a direction opposite to their initial goal (eg, many workers who discovered potent inhibitors of thrombosis were initially searching for procoagulants). Often, parallel work was proceeding in laboratories on either side of the Atlantic; in some cases, lines of discovery merged or diverged; in others, they continued its widespread therapeutic use by Wright and others in the 1940s. Link later developed warfarin as a rodenticide, but its use in humans soon followed in the 1950s. Vitamin K was discovered in the 1930s; its involvement in the mechanism of the anticoagulant agents was not delineated until the 1970s. The intrinsic ability of clotted blood to liquify and the fibrinolytic properties of normal urine were noted in the 1800s. Tillett and Sherry's group stumbled on the fibrinolytic properties of streptokinase in the 1930s and pioneered the therapeutic use of streptokinase in the 1940s and of urokinase in the 1960s. Several teams found tissue-type plasminogen activator in various body sites beginning in the 1940s, leading to its cloning and widespread use in the 1980s; anisoylated plasminogen-streptokinase activator complex is an example of rational drug design. The discoverers of these diverse agents have not only provided physicians with a potent armamentarium of antithrombotic drugs but also helped elucidate much basic science and vividly demonstrated the merits of perseverance, independent thought, and adherance to the scientific method. (Circulation. 1994; 89:432-449.) Key Words * aspirin * anticoagulants * thrombolytics ignorant of each others' existence. Discovery and development were not linear but proceeded in fits and starts; many important findings were ignored, only to be rediscovered or unknowingly replicated decades (or centuries) later. Importantly, all of the discoveries in antithrombotic agents led to important advances in our understanding not only of antithrombotic processes but also of procoagulant systems. The cast of characters come from Europe, Canada, and the United States; from esteemed and venerable urban centers of academia such as the Karolinska Institute, Johns Hopkins, Cornell, the Mayo Clinic, and Bellevue Hospital, as well as from unexpected locales such as the agricultural and veterinary facilities of Alberta, North Dakota, and Wisconsin; from the Oxfordshire countryside and nearby marshlands; and even from a private medical practice in Glendale, Calif. The innovators came from diverse backgrounds as country gentleman scholars and pastors, medical students, chemists and pharmacologists, veterinary pathologists and agriculturalists, or clinicians in medicine and surgery; working in academia, industry, or privately, they studied compounds ranging from simple organic acids and polycylic compounds (Fig 1) Reverend Stone set out in search of a cinchona substitute, guided by some simple principles. The first was the prevailing view at the time that many cures for illnesses were to be found right where the illness itself most commonly occurred. Aware of the old wives' tale about the white willow tree bark's use, Stone tasted it in 1757 and was impressed by its severe bitterness, reminiscent of Jesuit's bark. He wrote, "As this tree delights in a moist or wet soil where agues [fevers] chiefly abound, the general maxim that many natural maladies carry their cures along with them, or that their remedies lie not far from their causes, was so very apposite to this particular case that I could not help applying it. That this might be the intention of Providence had some little weight with me."5 In line with the then-popular "Doctrine of Signatures," fevers were thought to be more common in marshy areas where the white willow tree, Salix alba vulgaris (Fig 2) 144 The same year, Collen et a1145 pioneered the use of recombinant TPA in patients with acute MI. Randomized, controlled trials followed, with striking success, leading to FDA approval of intravenous TPA for acute MI in 1987 and for pulmonary embolism in 1990. Unlike the early TPAs derived from a variety of human tissues or from melanoma cell culture, current commercial TPA is prepared from recombinant DNA derived from human melanoma cells and expressed in the Chinese hamster ovary tissue culture system. Currently, only Genentech produces TPA; Burroughs Wellcome has abandoned development of its TPA, which differs from the native molecule by a single amino acid and by its double-chained structure. Genentech's product shares native TPA's amino acid sequence, single-chained structure, and possibly its glycosylation.
Current research into new thrombolytics centers around modified or fibrin-antibody-bound TPAs with improved fibrin specificity, prourokinase, chimeric molecules combining TPA and prourokinase, and entirely novel and potent thrombolytics such as vampire bat TPA and staphylokinase.
In conclusion, the stories of the discovery and development of the major agents used for thrombotic diseases are fascinating, triumphant landmarks in the annals of medicine. The long odysseys share recurrent themes of good fortune; unexpected breakthroughs, often by the most unlikely individuals; international competition and cooperation; unheeded visionaries; and false leads and blind alleys. But above all, they are vivid examples of the merits of maintaining an open, skeptical, and active mind. The rewards to the innovators have at times been fame and accolades; the rewards to the world have been a small, diverse group of potent, invaluable antithrombotic agents.
